^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
123P - Impact of the STK11 mutation on the response to immunotherapy
Published date:
03/17/2021
Excerpt:
...shortest OS was observed in the STK11mut/KRASmut population with an OS of 6.9 months, compared to 8.3 months in the STK11mut population and 33.9 months in the KRASmut population (CI95: 7.9–33.9/p = 0.018). These results are only significant between the KRASmut and KRASmut/STK11mut groups (p = 0.017).
Secondary therapy:
Chemotherapy
